share_log

英可瑞(300713.SZ):拟对瑞臻精密技术进行增资扩股

Incore (300713.SZ): Plans to increase capital and expand shares of Ruizhen Precision Technology

Gelonghui Finance ·  May 20 06:32

Gelonghui (300713.SZ) announced on May 20, that the company's holding subsidiary Shenzhen Ruizhen Precision Technology Co., Ltd. (“Target Company”) recently received a notice from shareholder PARKEUNA (US citizen) to decide not to participate in the investment target company due to its work schedule and place of work (PARKEUNA's registered capital of RMB 3.5 million, actual payment of RMB 0). After communicating with all shareholders, the target company agreed by all shareholders: PARKEUNA withdrew from the shareholders and reduced the registered capital pledged by the target company, and reduced the registered capital of the target company from RMB 35 million to RMB 31.5 million.

According to the company's strategic plan, taking into account the actual situation of the target company, the company held the 20th meeting of the 3rd board of directors on May 17, 2024 to review and pass the “Proposal on Capital Increase for the Holding Subsidiary”. It was agreed that after the capital reduction of the target company was completed, the company would increase the capital and expand the shares of the target company, and pledge the additional registered capital of RMB 3.50 million in monetary form, and the other original shareholders of the target company relinquished their priority subscription rights for this capital increase. After the capital increase was completed, the registered capital of the target company was finally changed to 35 million yuan, and the company's share ratio of the target company was changed from 65% to 75%. The target company is still a holding subsidiary of the company and will continue to be included in the scope of the company's consolidated statements.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment